Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H20N2O2 |
Molecular Weight | 260.3315 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1
InChI
InChIKey=FVNFBBAOMBJTST-UHFFFAOYSA-N
InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)
Molecular Formula | C15H20N2O2 |
Molecular Weight | 260.3315 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma. Fenspiride is marketed under the brand names Eurespal, Pneumorel, SYRESP, Oxofen and others. Erespal (fenspiride) is a drug with a bronchodilator and spasmolytic effect, which is often used in the complex therapy of bronchial asthma. Fenspiride has a clinically proven ability to increase the activity of the cilia of the bronchial ciliated epithelium, normalize the secretion of the bronchi and reduce its viscosity. Effectively removes bronchial obstruction, restores pulmonary gas exchange. Inhibits the metabolism of arachidonic acid, in parallel blocking histamine H1-receptors, since it is histamine that stimulates the chemical reactions of the transformation of arachidonic acid into the final metabolites-factors of inflammation. Reduces the production of other mediators of inflammation - serotonin and bradykinin.
It blocks α-adrenergic receptors, the activation of which increases the secretion of bronchial glands. The complex effect of fenspiride reduces the pathological effect of a number of factors that promote hypersecretion of anti-inflammatory substances and cause obstruction of the bronchial tree. Has a pronounced antispasmodic and myotropic effect.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: http://o-t-c.co.uk/eurespal-buy-online |
|||
Target ID: P16599 Gene ID: 103694380|||24835 Gene Symbol: Tnf Target Organism: Rattus norvegicus (Rat) |
|||
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9489859 |
4.16 null [pIC50] | ||
Target ID: CHEMBL2094125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9489859 |
3.44 null [pIC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Erespal Approved UseThe drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions):
pharyngitis;
Rhinopharyngitis;
laryngitis;
tracheitis;
Tracheobronchitis;
Bronchitis (with or without chronic respiratory failure);
bronchial asthma;
Respiratory symptoms with influenza, measles and whooping cough;
sinusitis;
otitis;
Infection of the respiratory system, in the symptomatic complex of which there is a cough. |
|||
Primary | Eurespal Approved UseIndications:
Rinofaringitis, laryngitis
— otitis, sinusitis
— rinotraheobronhit
— bronchitis
— bronchial asthma (maintenance therapy)
respiratory effects in measles, pertussis and influenza (syrup). |
|||
Primary | Eurespal Approved UseIndications:
Rinofaringitis, laryngitis
— otitis, sinusitis
— rinotraheobronhit
— bronchitis
— bronchial asthma (maintenance therapy)
respiratory effects in measles, pertussis and influenza (syrup). |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
206 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7901024/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
329.35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21899503/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
381.58 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21899503/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1034.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21899503/ |
80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.03 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7901024/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.73 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7901024/ |
80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10259.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21899503/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9576.89 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21899503/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
11208.73 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21899503/ |
80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7901024/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7901024/ |
80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
FENSPIRIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 2 times / day multiple, oral Recommended Dose: 80 mg, 2 times / day Route: oral Route: multiple Dose: 80 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Allergy... AEs leading to discontinuation/dose reduction: Allergy (4%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Allergy | 4% Disc. AE |
80 mg 2 times / day multiple, oral Recommended Dose: 80 mg, 2 times / day Route: oral Route: multiple Dose: 80 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Bronchial inflammation during chronic bronchitis, importance of fenspiride]. | 2002 Sep |
|
[Fenspiride-a new alternative on the therapy of obstructive lung disease]. | 2003 Apr-Jun |
|
[Effectiveness and tolerance of fenspiride treatment in chronic sinusitis. Results of the Polish multicenter study]. | 2005 |
|
[The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis]. | 2005 Aug |
|
[Usefulness of fenspiride in the treatment of acute otitis media in children]. | 2005 Jun |
|
Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease. | 2006 |
|
[Erespal in combined therapy of acute rhinosinusitis]. | 2006 |
|
[New pharmaceuticals in treatment of chronic dust bronchitis]. | 2007 |
|
[The effectiveness of fenspiride in the treatment of patients with chronic obstructive pulmonary disease]. | 2007 |
|
[Clinicofunctional condition and quality of life in patients with chronic obstructive pulmonary disease before and after outpatient treatment with fenspiride]. | 2008 |
Sample Use Guides
Tablets: One tablet (80 mg) twice-thrice a day. The maximum dose for a daily intake is 240 mg (3 tablets).Syrup: For 45-90 milliliters (3-6 tablespoons, respectively) per day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9163640
Curator's Comment: Fenspiride (10(-7)-10(-5) M) inhibited the histamine H1 receptor-induced Ca2+ increase in a lung epithelial cell line. Fenspiride (10(-5) M) abolished both phases of histamine-induced arachidonic acid release. https://www.ncbi.nlm.nih.gov/pubmed/9652346
Fenspiride (10(-6) to 10(-4) M) inhibited the nonadrenergic, noncholinergic (NANC) component of the contraction of the guinea-pig isolated main bronchus induced by EFS. Fenspiride significantly affected contractions induced by exogenously added substance P or [Nle10]-NKA(4-10) only at concentrations higher than 10(-3) M. In the guinea-pig perfused lung, fenspiride inhibited low pH- but not capsaicin-evoked release of CGRP. At higher concentrations (10(-4) M to 3x10(-4) M) fenspiride exhibited a significant inhibitory effect both on the cholinergic component of contractile response induced by EFS in the guinea-pig isolated main bronchus and on exogenously added acetylcholine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:13 GMT 2025
by
admin
on
Mon Mar 31 18:11:13 GMT 2025
|
Record UNII |
S983QC7HKM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03BX01
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
||
|
WHO-ATC |
R03BX01
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
||
|
WHO-VATC |
QR03DX03
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
||
|
WHO-ATC |
R03DX03
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL576127
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
DTXSID4023048
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
100000081488
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
5053-06-5
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
3344
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
SUB07596MIG
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
1163
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
FENSPIRIDE
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
DB08979
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
2577
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
m5296
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | Merck Index | ||
|
C80880
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
4335
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | RxNorm | ||
|
C084775
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
225-751-3
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY | |||
|
S983QC7HKM
Created by
admin on Mon Mar 31 18:11:13 GMT 2025 , Edited by admin on Mon Mar 31 18:11:13 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |